InCred Equities has set a target price of ₹4,796 for Privi Speciality Chemicals, representing significant upside potential from the current market price of ₹3,695.10. According to reports from The Hindu BusinessLine, the brokerage maintains an 'Add' rating on the stock, citing the company's evolution from a two-product aroma-chemical manufacturer in 1992 to an integrated supplier with more than 75 products and relationships with leading fragrance houses and FMCG companies.
The company is deploying between ₹12,000 crore and ₹12,500 crore over the next several years to significantly scale up its manufacturing footprint, aiming to capture a larger share of the aroma chemicals market worldwide. As reported by ETChemicals, this ambitious investment plan positions Privi at the forefront of India's specialty chemicals sector momentum, with the expansion including phased brownfield additions, the ramp-up of PRIGIV and new-product blocks. The company is investing around ₹1,200-1,250 crore to expand its capacity from 48,000 tonnes to 66,000-72,000 tonnes over the next three years.
Beyond traditional fragrance products, Privi is actively developing new molecules such as menthol, maltol, cyclopentanone, and furfural to diversify into adjacent segments like pharmaceuticals and flavours. According to ETChemicals, these compounds are expected to help the company broaden its addressable market and reinforce its standing in the specialty chemicals landscape. The company's shift towards higher-value woody, amber, floral, musk and fine-fragrance products should improve realisation, while new products such as menthol, maltol, cyclopentanone and furfural broaden the addressable market.
InCred expects gross margin to remain around 48 per cent and EBITDA margin at 25-26 per cent, supported by higher utilisation, better product mix and operating leverage. According to the brokerage's analysis, capacity ramp-up and improving realisation should lift EPS to around ₹123 in FY28F and ₹151 in FY29F. The target price of ₹4,796 is derived by applying a conservative 35x one-year forward P/E to the average FY28F-29F EPS of ₹137. InCred Research projects that Privi will maintain stable EBITDA margins in the 25 to 26 percent range as the product mix shifts towards higher-value offerings and operational leverage improves.
One of Privi's defining competitive advantages lies in its backward integration into pine chemistry, sourcing crude sulphate turpentine and gum turpentine oil from an extensive network of over 60 mills across North America, Europe, Brazil, and Indonesia. As reported by ETChemicals, this approach shields the company from volatility associated with petroleum-based raw materials. The company is also exploring biotechnology-based products such as ferulic acid and bio-vanillin, though commercial realisation of these green chemistry initiatives is anticipated to take several more years. Analysts believe that the synergy of backward integration, deep customer relationships, and ongoing product innovation will continue to underpin Privi's growth trajectory as the specialty chemicals sector becomes increasingly vital to global consumer goods and pharmaceutical industries.
